Literature DB >> 15226165

Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study.

John G O'Meara1, Sharon L R Kardia, Jeffrey J Armon, C Andrew Brown, Eric Boerwinkle, Stephen T Turner.   

Abstract

BACKGROUND: Two ethnically different, community-based samples of hypertensive adults were evaluated to determine the prevalence of dyslipidemia and how often dyslipidemia is drug-treated and controlled by such treatment.
METHODS: We studied 1286 non-Hispanic black hypertensive subjects from Jackson and 1070 non-Hispanic white hypertensive subjects from Rochester who participated in the Genetic Epidemiology Network of Arteriopathy study. Subjects were categorized according to presence of coronary heart disease and risk factors for coronary heart disease.
RESULTS: Prevalence of dyslipidemia was significantly greater among whites than blacks (women, 64.7% vs 49.5%; and men, 78.4% vs 56.7%; P<.001 for both) and among men than women (P</=.02 in each ethnic group). Among dyslipidemic subjects, treatment with lipid-regulating drugs was significantly more common among whites than blacks (women, 25.4% vs 16.4%, P =.001; and men, 32.6% vs 12.8%; P<.001), and among whites, treatment was significantly more common among men than women (P =.03). With drug treatment, control of dyslipidemia varied from 33.9% (white men) to 51.9% (black men), but the differences among ethnic-sex groups were not statistically significant.
CONCLUSIONS: Dyslipidemia is highly prevalent in hypertensive adults. Fewer than one third of these adults are drug-treated, and fewer than half of those treated achieve recommended goals. Our findings suggest that an alarming 9 of 10 dyslipidemic hypertensive adults have untreated or undertreated dyslipidemia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15226165     DOI: 10.1001/archinte.164.12.1313

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  66 in total

1.  Trends in cardiovascular risk factor levels in the Minnesota Heart Survey (1980-2002) as compared with the National Health and Nutrition Examination Survey (1976-2002): A partial explanation for Minnesota's low cardiovascular disease mortality?

Authors:  Huifen Wang; Lyn M Steffen; David R Jacobs; Xia Zhou; Henry Blackburn; Alan K Berger; Kristian B Filion; Russell V Luepker
Journal:  Am J Epidemiol       Date:  2011-01-27       Impact factor: 4.897

2.  Blood lipids, infection, and inflammatory markers in the Tsimane of Bolivia.

Authors:  Sarinnapha Vasunilashorn; Eileen M Crimmins; Jung Ki Kim; Jeff Winking; Michael Gurven; Hillard Kaplan; Caleb E Finch
Journal:  Am J Hum Biol       Date:  2010 Nov-Dec       Impact factor: 1.937

Review 3.  Expanding the definition of hypertension to incorporate global cardiovascular risk.

Authors:  Nitin Khosla; Henry R Black
Journal:  Curr Hypertens Rep       Date:  2006-10       Impact factor: 5.369

4.  Statin therapy depresses total body fat oxidation in the absence of genetic limitations to fat oxidation.

Authors:  N M Fisher; K Meksawan; A Limprasertkul; P J Isackson; D R Pendergast; G D Vladutiu
Journal:  J Inherit Metab Dis       Date:  2007-04-05       Impact factor: 4.982

5.  Prevalence and treatment of isolated and concurrent hypertension and hypercholesterolaemia in the United Kingdom.

Authors:  Thomas M MacDonald; Steven V Morant
Journal:  Br J Clin Pharmacol       Date:  2008-02-14       Impact factor: 4.335

6.  Methods for estimation of disparities in medication use in an observational cohort study: results from the Multi-Ethnic Study of Atherosclerosis.

Authors:  Robyn L McClelland; Neal W Jorgensen; Wendy S Post; Moyses Szklo; Richard A Kronmal
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-02-04       Impact factor: 2.890

7.  The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity.

Authors:  Jun-ichi Hanai; Peirang Cao; Preeti Tanksale; Shintaro Imamura; Eriko Koshimizu; Jinghui Zhao; Shuji Kishi; Michiaki Yamashita; Paul S Phillips; Vikas P Sukhatme; Stewart H Lecker
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

8.  The heart truth professional education campaign on women and heart disease: needs assessment and evaluation results.

Authors:  Janet Pregler; Karen M Freund; Mary Kleinman; Maureen G Phipps; Rose S Fife; Becky Gams; Ana E Núñez; Margaret R Seaver; Cathy J Lazarus; Nancy C Raymond; Joan Briller; Sebastian Uijtdehaage; Cindy S Moskovic; Gretchen Guiton; Michele David; Geralde V Gabeau; Stacie Geller; Kelli Meekma; Christopher Moore; Candace Robertson; Gloria Sarto
Journal:  J Womens Health (Larchmt)       Date:  2009-10       Impact factor: 2.681

9.  Higher plasma leptin levels are associated with reduced left ventricular mass and left ventricular diastolic stiffness in black women: insights from the Genetic Epidemiology Network of Arteriopathy (GENOA) study.

Authors:  Daisuke Kamimura; Takeki Suzuki; Wanmei Wang; Matthew deShazo; John E Hall; Michael D Winniford; Iftikhar J Kullo; Thomas H Mosley; Kenneth R Butler; Michael E Hall
Journal:  Hypertens Res       Date:  2018-06-15       Impact factor: 3.872

10.  Effect of gender, caregiver, on cholesterol control and statin use for secondary prevention among hospitalized patients with coronary heart disease.

Authors:  Gmerice Hammond; Heidi Mochari-Greenberger; Ming Liao; Lori Mosca
Journal:  Am J Cardiol       Date:  2012-08-15       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.